Printer Friendly

PHARMOS RESEARCHERS PRESENT DATA ON THE THERAPEUTIC VALUE OF HU-211, A NEUROPROTECTANT IN HEAD TRAUMA AND STROKE

 MARTIN, Slovak Republic, Aug. 19 /PRNewswire/ -- Researchers from Pharmos are presenting recent findings on HU-211 this week at the 6th Annual International Symposium, New Frontiers in the Biochemistry and Biophysics on Diagnosis and Treatment of Stroke, Neurotrauma and other Neurological Diseases. Dr. Anat Biegon, director of pharmacology at Pharmos Corporation describes the results of animal studies in a rat model (Shohami et al., 1993) demonstrating the efficacy of HU-211 in head trauma, as measured with MRI scans. Next week, Senior Scientist A. Bar-Joseph will present data on HU-211 in stroke at the 14th Biennial International Society for Neurochemistry (ISN) meeting in Montpellier, France. Dr. IIaim Aviv, chief executive officer of Pharmos said, "The results of the studies being presented provide further evidence that HU- 211 may be a valuable neuroprotective agent in both head trauma and stroke-related injury."
 Dr. Biegon presents results of the study, "MRI study of Rat Brain Edema After Head Trauma: Effects of HU-211, A Nonpsychotropic Cannabinoid." Head trauma was induced by a weight drop device onto the skull of anesthetized rats and MRIs were taken. HU-211 was injected one hour after the insult and the edema volume was monitored using MRI scans, immediately and 24 hours after the trauma. The results demonstrate that treatment with HU-211 markedly reduced the spread of edema, as exhibited by the lower edema in the brain. The intracranial pressure evoked by the evolving edema is the major cause of paralysis or death due to head injuries. Therefore, the approach of attenuating this reaction has significant potential in treating head trauma. To date, no drugs are approved of treating head trauma which efficiently reduce the spread of edema. In addition, at the ISN meeting (Aug. 22, 1993) A. Bar. Joseph, DVM, Senior Scientists at Pharmos, will present data demonstrating the anti-ischemic activity of HU-211 in several animal models.
 The results of these studies suggest that HU-211 may be effective in the treatment of head trauma and stroke. Pharmos plans to begin clinical trials using HU-211 to treat head trauma patients.
 Pharmos Corporation is engaged in the development of novel pharmaceuticals based on innovative drug delivery technologies targeting diseases of the eye, principally glaucoma and ocular inflammation, and the brain, principally stroke and head trauma.
 -0- 8/19/93
 /CONTACT: Stephen R. Streber, president and COO of Pharmos Corporation, 212-838-0087, or Anthony J. Russo of Noonan/Russo Communications, 212-696-4455, or Donald C. Weinberger of Strategic Grown International, 212-826-9622/
 (PARS)


CO: Pharmos Corporation ST: New York IN: MTC SU:

LG-TS -- NY045 -- 4369 08/19/93 13:38 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 19, 1993
Words:424
Previous Article:BLUE CROSS AND BLUE SHIELD OF MINNESOTA SELECTS CASE FOLEY SACKETT AS NEW AD AGENCY -- STRATEGIC CAPABILITIES KEY TO NEW RELATIONSHIP
Next Article:YATI THE PERFECT SHOPPING EXPERIENCE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters